A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101530765 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6651 (Electronic) Linking ISSN: 20726651 NLM ISO Abbreviation: Toxins (Basel) Subsets: MEDLINE

Original Publication: Basel : MDPI

Botulinum Toxins, Type A*/adverse effects ; Neuromuscular Agents*/adverse effects; Adult ; Humans ; Longitudinal Studies ; Muscle Spasticity/drug therapy ; Prospective Studies ; Quality of Life ; Retrospective Studies ; Treatment Outcome ; United Kingdom

Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015-2017) or aboBoNT-A (Cohort 2; 2017-2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3-46.9) and 47.8 (43.7-51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, -5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non-treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.

Community Ment Health J. 1968 Dec;4(6):443-53. (PMID: 24185570)
JAMA Facial Plast Surg. 2018 Mar 01;20(2):141-147. (PMID: 28973094)
J Cent Nerv Syst Dis. 2021 Sep 20;13:11795735211036576. (PMID: 34566442)
J Rehabil Med. 2021 Jan 1;53(1):jrm00133. (PMID: 33206198)
J Med Econ. 2022 Jan-Dec;25(1):919-929. (PMID: 35730362)
J Neural Transm (Vienna). 2008;115(4):607-16. (PMID: 18389166)
J Rehabil Med Clin Commun. 2018 Sep 21;1:1000004. (PMID: 33884109)
Med Devices (Auckl). 2012;5:97-101. (PMID: 23204875)
Front Neurol. 2020 Sep 25;11:576117. (PMID: 33101184)
Toxins (Basel). 2020 Dec 04;12(12):. (PMID: 33291807)
J Med Econ. 2021 Jan-Dec;24(1):949-961. (PMID: 34340647)
Clin Anat. 2023 Oct;36(7):964-970. (PMID: 36606364)
Pan Afr Med J. 2020 Feb 25;35:55. (PMID: 32523646)
J Rehabil Med. 2021 Jan 1;53(1):jrm00134. (PMID: 33057730)
JMIR Public Health Surveill. 2020 Dec 7;6(4):e17928. (PMID: 33284124)
Neurology. 2016 May 10;86(19):1818-26. (PMID: 27164716)
Clinicoecon Outcomes Res. 2015 Sep 09;7:441-9. (PMID: 26392782)
J Rehabil Med. 2021 Feb 24;53(2):jrm00157. (PMID: 33616192)
Health Qual Life Outcomes. 2020 Mar 4;18(1):51. (PMID: 32131842)
Clin Neurol Neurosurg. 2021 Oct;209:106889. (PMID: 34461363)
Sci Rep. 2023 Jul 10;13(1):11167. (PMID: 37430018)
Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22. (PMID: 25750484)
J Clin Aesthet Dermatol. 2011 Sep;4(9):43-9. (PMID: 21938269)
Disabil Rehabil. 2005 Jan 7-21;27(1-2):2-6. (PMID: 15799140)
Surg Radiol Anat. 2023 Aug;45(8):1055-1062. (PMID: 37294437)
Toxins (Basel). 2018 Dec 13;10(12):. (PMID: 30551641)

Keywords: aboBoNT-A; abobotulinumtoxinA; adult limb spasticity; botulinumtoxinA; clinical practice; healthcare cost; onaBoNT-A; onabotulinumtoxinA; rehabilitation; stroke

EC 3.4.24.69 (Botulinum Toxins, Type A)
0 (Neuromuscular Agents)

Date Created: 20230927 Date Completed: 20231004 Latest Revision: 20231009

20231010

PMC10534376

10.3390/toxins15090532

37755958